Results 121 to 130 of about 34,123 (218)

Identification of drug repurposing candidates for the treatment of polycystic kidney disease

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 16, Page 5082-5101, August 2026.
Background and Purpose Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end‐stage renal disease with limited treatment options. Drug repurposing offers a promising strategy to find effective treatments. Experimental Approach We identified birinapant, bardoxolone methyl and salicylic acid as repurposing candidates for ADPKD and
Alina Meyer   +9 more
wiley   +1 more source

TREM2 in Macrophages Promotes Renal Fibrosis via Activation of β‐Catenin Signalling Pathway in Obstructive Nephropathy

open access: yesCell Proliferation, Volume 59, Issue 8, August 2026.
Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) promotes obstructive nephropathy progression by activating the β‐catenin signalling pathway, driving M2 macrophage polarisation, migration and fibrogenic gene expression. targeted inhibition of TREM2 thus represents a promising novel strategy against renal fibrosis.
Jia Wei   +7 more
wiley   +1 more source

A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases. [PDF]

open access: yesJ Am Soc Nephrol
Stanajic-Petrovic G   +26 more
europepmc   +1 more source

Recipient Selection and Outcomes After Out‐of‐Sequence Kidney Allocation Since Implementation of Kidney Allocation System 250 (KAS250): A Single‐Center Experience

open access: yesClinical Transplantation, Volume 40, Issue 8, August 2026.
ABSTRACT Introduction Allocation out of sequence (AOOS) of kidneys has increased after KAS250 and raised concerns regarding transparency and equitable recipient selection. Less is known about recipient selection and outcomes at individual centers. Methods We performed a single‐center retrospective study of adult deceased donor kidney transplants at the
Sandesh Parajuli   +3 more
wiley   +1 more source

Short‐Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open‐Label, Randomised Controlled Trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7380-7392, August 2026.
ABSTRACT Aims This study aimed to assess the effects of low‐dose tirzepatide combined with metformin (COM) versus metformin (MET) monotherapy in overweight/obese women with polycystic ovary syndrome (PCOS). Materials and Methods Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET ...
Zhuoran Yang   +7 more
wiley   +1 more source

High level of patient satisfaction with incremental haemodialysis: insights from a single‐centre patient‐reported experience study

open access: yesInternal Medicine Journal, Volume 56, Issue 8, Page 1438-1442, August 2026.
Abstract A single‐centre, anonymous survey study was conducted to investigate patient experience and quality of life (Kidney Disease Quality of Life‐36) in individuals receiving incremental haemodialysis, with all 20 eligible patients participating.
Kavita L. Dilip   +2 more
wiley   +1 more source

Amino acid homeostasis in the kidney: Physiological roles and pathological dysregulation

open access: yesPhysiological Reports, Volume 14, Issue 15, August 2026.
Abstract Amino acids are fundamental to life as protein building blocks and key regulators of metabolism and signaling. The kidney plays a critical, yet underappreciated, role in amino acid homeostasis through three interconnected pillars: selective glomerular filtration, efficient tubular reabsorption, and metabolic processing, which includes de novo ...
Shuo Liu   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy